Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose We investigated the clinical efficacy of immune checkpoint blocker (ICB) therapy for metastatic or advanced melanoma in Korean patients. As well, we assessed whether the effects of ICBs can be enhanced by combination therapy with palliative radiotherapy (RT). Materials and Methods We retrospectively reviewed the records of 127 patients with metastatic melanoma who received ICB with or without palliative RT between 2014 and 2018. The melanoma subtypes were classified as follows: chronic sun-damaged (CSD), acral, mucosal, and uveal. The primary endpoint was the objective response rate (ORR). Results The overall ORR was 15%, with 11 complete and eight partial responses. ORRs for CSD, acral/mucosal, and uveal melanomas were 50%, 16.5%, and 0%, respectively (p=0.009). In addition to the subtype, stage at treatment, total tumor burden at treatment, and ICB type were significantly associated with ORR (all p < 0.05). Palliative RT was administered in 44% of patients during the treatment, and it did not affect ORR. Clinical responders to ICB therapy exhibited significantly higher 1-year progression-free and overall survival rates than nonresponders. Conclusion ORR for ICB monotherapy in Korean patients with melanoma is relatively modest compared with that in Western patients because the non-CSD subtypes are predominant in the Korean population. Our findings regarding combination therapy with ICB provided a rationale for the initiation of our phase II study (NCT04017897).
Abstract
Purpose We investigated the clinical efficacy of immune checkpoint blocker (ICB) therapy for metastatic or advanced melanoma in Korean patients. As well, we assessed whether the effects of ICBs can be enhanced by combination therapy with palliative radiotherapy (RT). Materials and Methods We retrospectively reviewed the records of 127 patients with metastatic melanoma who received ICB with or without palliative RT between 2014 and 2018. The melanoma subtypes were classified as follows: chronic sun-damaged (CSD), acral, mucosal, and uveal. The primary endpoint was the objective response rate (ORR). Results The overall ORR was 15%, with 11 complete and eight partial responses. ORRs for CSD, acral/mucosal, and uveal melanomas were 50%, 16.5%, and 0%, respectively (p=0.009). In addition to the subtype, stage at treatment, total tumor burden at treatment, and ICB type were significantly associated with ORR (all p < 0.05). Palliative RT was administered in 44% of patients during the treatment, and it did not affect ORR. Clinical responders to ICB therapy exhibited significantly higher 1-year progression-free and overall survival rates than nonresponders. Conclusion ORR for ICB monotherapy in Korean patients with melanoma is relatively modest compared with that in Western patients because the non-CSD subtypes are predominant in the Korean population. Our findings regarding combination therapy with ICB provided a rationale for the initiation of our phase II study (NCT04017897).
참고문헌 (30)
- Postow MA, "Nivolumab and ipilimumab versus ipilimumab in untreated melanoma", N Engl J Med, 372, pp.2006~2017 (2015)
- Hodi FS, "Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma : 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial", Lancet Oncol, 17, pp.1558~1568 (2016)
- Bradford PT, "Acral lentiginous melanoma : incidence and survival patterns in the United States, 1986-2005", Arch Dermatol, 145, pp.427~434 (2009)
- Curtin JA, "Distinct sets of genetic alterations in melanoma", N Engl J Med, 353, pp.2135~2147 (2005)
- Shoushtari AN, "The efficacy of anti-PD-1 agents in acral and mucosal melanoma", Cancer, 122, pp.3354~3362 (2016)
- Hayward NK, "Whole-genome landscapes of major melanoma subtypes", Nature, 545, pp.175~180 (2017)
- Ribas A, "Cancer immunotherapy using checkpoint blockade", Science, 359, pp.1350~1355 (2018)
- Wei Y, "Efficacy and safety of combination immunotherapy for malignant solid tumors : a systematic review and meta-analysis", Crit Rev Oncol Hematol, 138, pp.178~189 (2019)
- Pfirschke C, "Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy", Immunity, 44, pp.343~354 (2016)
- Fukumura D, "Enhancing cancer immunotherapy using antiangiogenics : opportunities and challenges", Nat Rev Clin Oncol, 15, pp.325~340 (2018)
- Demaria S, "Role of local radiation therapy in cancer immunotherapy", JAMA Oncol, 1, pp.1325~1332 (2015)
- Vanpouille-Box C, "DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity", Nat Commun, 8, pp.15618~ (2017)
- Shargel L, "Applied biopharmaceutics and pharmacokinetics" (2015), McGraw-Hill Education
- Seymour L, "iRECIST : guidelines for response criteria for use in trials testing immunotherapeutics", Lancet Oncol, 18, pp.e143~e152 (2017)
- Somarouthu B, "Immune-related tumour response assessment criteria : a comprehensive review", Br J Radiol, 91, pp.2017~0457 (2018)
- Tas F, "Acral lentiginous melanoma is associated with certain poor prognostic histopathological factors but may not be correlated with nodal involvement, recurrence, and a worse survival", Pathobiology, 85, pp.227~231 (2018)
- Bello DM, "Prognosis of acral melanoma : a series of 281 patients", Ann Surg Oncol, 20, pp.3618~3625 (2013)
- 노미령, "Treatment and Outcomes of Melanoma in Acral Location in Korean Patients", Yonsei Medical Journal, 51(4), pp.562~568 (2010), 연세대학교의과대학
- Maeda T, "Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients", Br J Dermatol, 180, pp.1230~1231 (2019)
- Reits EA, "Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy", J Exp Med, 203, pp.1259~1271 (2006)
- Lhuillier C, "Radiation therapy and anti-tumor immunity : exposing immunogenic mutations to the immune system", Genome Med, 11, pp.40~ (2019)
- Twyman-Saint Victor C, "Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer", Nature, 520, pp.373~377 (2015)
- Hiniker SM, "A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma", Int J Radiat Oncol Biol Phys, 96, pp.578~588 (2016)
- Koller KM, "Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone", Cancer Biol Ther, 18, pp.36~42 (2017)
- Mowery YM, "Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma : a bi-institutional study", Radiother Oncol, 138, pp.114~120 (2019)
- Antonia SJ, "Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC", N Engl J Med, 379, pp.2342~2350 (2018)
- McGee HM, "Stereotactic ablative radiation therapy induces systemic differences in peripheral blood immunophenotype dependent on irradiated site", Int J Radiat Oncol Biol Phys, 101, pp.1259~1270 (2018)
- Couty E, "Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma : a real-life report : radiation", systemic drug combo in metastatic melanoma, 2019, pp.83, 881~892
- Amin NP, "Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy", Adv Radiat Oncol, 3, pp.399~404 (2018)
- "The combination of anti-PD-1 with radiotherapy in previously untreated metastatic melanoma" (2019)[URL]